Literature DB >> 1261015

Technical pitfalls in measurement of venous plasma NH3 concentration.

G G Gerron, J D Ansley, J W Isaacs, M H Kutner, D Rudman.   

Abstract

Measurement of venous plasma NH3 in normal subjects by the ion-exchange method of Forman [Clin. Chem. 10, 497 (1964)] in a hospital clinical laboratory gave a mean value of 640 mug/liter (range, 300-1320 mug/liter; intraassay, intra-individual, and inter-individual coefficients of variation, 8, 47, and 47%, respectively). The following conditions adversely affect the reproducibility of the test: pollution of laboratory atmosphere and glassware by NH3-containing detergents; smoking by patient or analyst; delay, turbulence, or use of heparin lock in venipuncture; delay or warming of plasma above degrees C before mixing it with resin; and delay in colorimetric analysis of resin eluate. When these sources of error were eliminated, the mean value for normals was reduced to 330 mug/liter, the range was narrowed to 220-470 mug/liter, and the above-mentioned CV's were 5, 16, and 17%, respectively. With the precautions cited, furthermore, the intra-assay and intra-individual CV's for fasting NH3 concentration in cirrhotic patients were similarly reduced. An NH3 tolerance test was done by administering a standard dose of NH4Cl to patients and measuring venous plasma NH3 at 0, 15, 30, 60, and 90 min; the NH3 tolerance was quantified from the area under the curve relating concentration to time (mug - min/liter). As measured in the clinical laboratory, NH3 tolerance of cirrhotic patients showed intra-assay and intra-individual CV's of 50 to 90%. When the tolerance tests were repeated in the same subjects with the laboratory precautions listed above, these CV's were reduced to 8-15%.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1261015

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  8 in total

1.  Breath ammonia testing for diagnosis of hepatic encephalopathy.

Authors:  Suja DuBois; Sue Eng; Renuka Bhattacharya; Steve Rulyak; Todd Hubbard; David Putnam; David J Kearney
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

2.  Tyrosine transaminase activity in normal and cirrhotic liver.

Authors:  J M Henderson; B A Faraj; F M Ali; D Rudman
Journal:  Dig Dis Sci       Date:  1981-02       Impact factor: 3.199

3.  A randomized, controlled trial of the distal splenorenal shunt.

Authors:  L F Rikkers; D Rudman; J T Galambos; J T Fulenwider; W J Millikan; M Kutner; R B Smith; A A Salam; P J Sones; W D Warren
Journal:  Ann Surg       Date:  1978-09       Impact factor: 12.969

4.  Total parenteral nutrition with F080 in cirrhotics with subclinical encephalopathy.

Authors:  W J Millikan; J M Henderson; W D Warren; S P Riepe; M H Kutner; L Wright-Bacon; C Epstein; R B Parks
Journal:  Ann Surg       Date:  1983-03       Impact factor: 12.969

5.  Urinary pyrimidine excretion in arginase deficiency.

Authors:  E W Naylor; S D Cederbaum
Journal:  J Inherit Metab Dis       Date:  1981       Impact factor: 4.982

6.  Ten years portal hypertensive surgery at Emory. Results and new perspectives.

Authors:  W D Warren; W J Millikan; J M Henderson; L Wright; M Kutner; R B Smith; J T Fulenwider; A A Salam; J T Galambos
Journal:  Ann Surg       Date:  1982-05       Impact factor: 12.969

7.  Comparison of the effects of Hepatic-Aid and a Casein modular diet on encephalopathy, plasma amino acids, and nitrogen balance in cirrhotic patients.

Authors:  A McGhee; J M Henderson; W J Millikan; J C Bleier; R Vogel; M Kassouny; D Rudman
Journal:  Ann Surg       Date:  1983-03       Impact factor: 12.969

8.  Noncirrhotic portal vein thrombosis. Physiology before and after shunts.

Authors:  W D Warren; W J Millikan; R B Smith; E B Rypins; J M Henderson; A A Salam; T Hersh; J T Galambos; B A Faraj
Journal:  Ann Surg       Date:  1980-09       Impact factor: 12.969

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.